340B Drug Pricing Program
A federal program established under Section 340B of the Public Health Service Act that requires drug manufacturers to sell outpatient drugs to qualifying covered entities at significantly reduced prices (the 340B ceiling price is calculated from average manufacturer price (AMP) minus the unit rebate amount (URA), typically yielding 25-50% off list). Covered entities that participate in 340B can then dispense those drugs to patients and bill payers at standard reimbursement rates, generating a margin. The 340B program is administered by the Health Resources and Services Administration (HRSA).
Why this matters for your clinic
For eligible covered entities, 340B is a meaningful revenue opportunity. The margin between acquisition cost and reimbursement on outpatient drugs can generate millions of dollars per year for qualifying hospitals and health systems. Federally Qualified Health Centers (FQHCs), rural referral centers, children's hospitals, and disproportionate share hospitals are among the entities that qualify.
Independent outpatient clinics generally do not qualify as covered entities directly. However, if your clinic is affiliated with a qualifying entity (for example, if you operate as an off-site outpatient facility of a qualifying hospital), you may be eligible to participate through the parent entity's 340B registration. HRSA eligibility rules for off-site facilities are detailed and change periodically.
The 340B program has been the subject of significant litigation and regulatory activity, particularly around contract pharmacy arrangements (where covered entities dispense 340B drugs through third-party pharmacies). Drug manufacturer restrictions on contract pharmacy use have been contested in federal courts. Clinic owners with potential 340B eligibility should consult HRSA guidance and experienced 340B counsel before assuming access to the program.
What good looks like
HRSA publishes 340B program statistics including the number of registered covered entities and disproportionate share adjustment data. HRSA's Office of Pharmacy Affairs oversees 340B audits and compliance. Drug manufacturers and covered entity trade groups publish periodic analyses of 340B market dynamics.
Example
An FQHC-qualified community health center purchases a branded drug at the 340B ceiling price of $28 per unit. The payer's allowed amount for the same drug on a covered patient's claim is $185. The margin on each dispensing is $157. Across 500 units per month, that is $78,500 per month in gross 340B margin, which the FQHC reinvests in expanding patient services. The FQHC must maintain accurate patient eligibility and dispensing records to remain in HRSA compliance.
From Sorso
340B eligibility and compliance is a specialized area that requires dedicated expertise. For the FQHCs and DSH-affiliated clinics we work with that participate in 340B, the program is a significant income source, but the compliance overhead is real and the regulatory environment is shifting.
Related terms
Founder of Sorso. 19 years in corporate finance. Managed a $450M loan portfolio before building a fractional CFO firm exclusively for healthcare clinics.
Want to see how your practice measures up?
Take the 4-minute financial assessment. It is free, and it will show you where your practice is leaking money.